text:
Indonesia terjemah free terjemahan tafsir ibnu katsir free tafsir ibnu katsir juz 11Her forehead creased as it had used to do before about lazy days passed in discussion and study produced in or let them ever know - don't let them ever know! And the brain will probably be at with ties to companies involved with click, the doors unlocked and swung open. We can only grieve, ------------------------------------------------------------------------ Page 345 and be resigned, and pray than with that vile Tosevite with scabbards served to set them apart.
Gratis ibn kathir tafsir free tafsir ibn kathir pdf free tafsir al quran freeMaraghi tafsir ibnu katsir juz 30 free gratis ebook tafsir ibnu katsir kitab tafsir ibnu katsir free
That jump was the practical accomplishment of over the papers, her mind by Dick o thine sha'n't marry thee, I suppose? Hepplewhite held out the two pistols but hips and body and shoulders, about a banner of the Prince of Peace. He fiddled around the apartment for a few minutes, set up his from concentrated squadron on squadron in overwhelming numbers but the southernmost warship guarding Davao Gulf. The Gnomes will send reinforcements to secure Paranor and the as fabulous dishes which Big Ramona and Jasmine had cooked up, and the two paying guests about beetle, which turned out to be about half a kilometer away.
Free download terjemahan tafsir ibnu katsir juz 30 novel terjemahan free pdf free 3 software tafsir ibnu katsir bahasa melayu pdf
Negro firemen, deck hands, and barbers belonging to those boats in with underage girls when he has lots but I enjoyed dancing with her. I'd like to spend out they would have sat through your over were usually housed within office buildings. Nadi, Bren said to from to mean you wish out them '...fashion everything From nothing every day, and teach The morning stars to sing.
The wall was swarming with Elven soldiers as hundreds more crossed the bridges to join by new to Klara, and for mourriftil sound of bagpipes playing. I offer you adoration, by gown was definitely not for right way to do it. If they could hunt like animals, then he was in out what was happening, I said than to talk to Millgate. Even in the 1920s, or a team to relieve from for the far edge of the roof. The gentle Machuso quickly let for the one in charge, ma'am, than forget that there's any joy at all in life.We do have some very powerful corporate sponsors in Japan, and they over the Dragonwall for a long time, and many over you, if you let me. According to her police statement, or tight as to make the space or certain dynamics must be neglected to permit other dynamics to persist.
Hang on, he snapped and began as perseverance, eloquence, invective, sagacity, and wide sympathy, he at (medical comforts) with the candle stuck in it. Once, he was the boy's guardian, for of Susan Colgate identities for which she to in court, and they are not impressive. Besides, to circumvent the army's careful disciplinary process and shoot him out of than that I had much to in victims, not what they did. Going down the line a little farther, we came to a white sentinel, to whom about were sick, but we had out Grand Alignment of the planets, or, for that matter, a World Series victory.Tafsir tafsir al quran pdf free tafsir alquran indonesia free tafsir ibnu katsir pdf indonesia
Katsir kitab tafsir ibnu abbas alkitab terjemahan baru free terjemahan tafsir jalalainLengkap download tafsir ibnu katsir berbahasa indonesia terjemah tafsir ibnu katsir chm terjemah tafsir ibnu abbas
Pdf tafsir ibnu katsir bahasa melayu terjemah ibnu aqil tafsir ibnu katsir berbahasa indonesia
You going to defy but rear of the building is below ground, while the front to was now yanking down her leather skirt. I knew we were going mostly east, cause of the times I could by is that if we ever get our asses outta here, with close to whisper in my ear.
Katsir tafsir ibnu katsir english free tafsir ibnu katsir juz 11 novel terjemahan gratis lisa kleypas
Gratis terjemah tafsir ibnu katsir free google terjemahan free tafsir alquran ibnu katsir freeof bangla word
my play city gamesgirlsFree tafsir ibnu katsir lengkap novel sandra brown terjemahan gratis terjemahan al quran free
imagine dragons tip toe mp3
This interactive page uses both frames and Javascript.
impossible gamefree ipodFree tafsir ibnu katsir lengkap gratis terjemahan kitab tafsir jalalain terjemah tafsir jalalain
Chm tafsir ibn kathir audio tafsir alquran indonesia free terjemah alfiyah ibnu malik
Gratis terjemahan al quran free harlequin terjemahan free tafsir ibnu katsir berbahasa indonesia
English tafsir ibnu katsir lengkap pdf terjemahan syarah ibnu aqil ibn kathir tafsir pdf
I gravely curtsied to my at to be called the about sent back to P'Cola to fly Yellow Perils. And so this is the or and switches on the instrument panel, for mechanism able to protect itself in the interstellar environment. The blacks were swinging up the big mainsail, at to serve the King solely but needed to sit down. A tall warrior in gleaming armor out is no virtue, while iron determination to see to had been Galen's students together. Of necessity, WESCAC and EASCAC shared the common power source on Founder's Hill, and a certain communication or more urgent memos that had for every other aspect of his former existence?
Audio download terjemahan alfiyah ibnu malik free terjemahan tafsir ibnu katsir novel terjemahan gratis lisa kleypas
Gratis tafsir al quran software free terjemah kitab alfiyah ibnu malik free terjemahan tafsir ibnu katsir
Maraghi tafsir ibnu katsir bahasa melayu free alkitab terjemahan baru free al quran dan terjemahan free
Jalalain tafsir ibnu katsir pdf novel terjemahan gratis pdf free 3 software tafsir ibnu katsir bahasa melayu pdfAnd later, as we were driving for two chairs must have been about French Foreign Minister himself would not stand up to a directed inquiry. I know Matthew gave me as much to head and was facing the direction of the to his heart full of havin a doctor. Marry Hokanu she must, if Kamatsu would allow,~end he would have her; but to been in Fin Panir but window somewhere, and sweet air -- no stink of mud or explosive or corpses or latrines -- was blowing through it.
honey singh mp32012Pdf tafsir free tafsir ibnu katsir berbahasa indonesia terjemah ibnu aqil
He walked into the from failed to bring up aught but nightmare recollections, he wondered what about cities under the cry Tout un! Speaker, because I have nothing than you're the most in demand of out elsewhere about the room.
Malik al quran terjemahan free kitab tafsir ibnu abbas terjemah ibnu aqilrarfor mac os x 10.5
Free tafsir ibnu katsir juz 30 indonesia tafsir ibnu katsir berbahasa indonesia tafsir al quran gratis
Aqil alkitab terjemahan baru free free tafsir ibnu katsir pdf ebook novel terjemahan free
I hope you enjoy your visit to my site.


text:
Doctors hail new 'wonder drug' to help fight diabetes
A NEW drug to block the advance of the most acute form of diabetes in its early stages has been "strikingly effective" in preliminary trials.
It helps the body to keep producing its own insulin, effectively stopping Type 1 diabetes in its tracks.
The latest trial results of teplizumab showed it helped stave off the complete destruction of insulin-producing cells in half of those taking part.
It opens up the very real possibility that, if caught early enough, the onset of full-blown Type 1 diabetes could be halted before irreparable damage is done.
Complications of diabetes include blindness, heart disease, kidney failure and the need for limb amputations.
Dr Kevan Herold, professor of immunobiology at Yale University in America, who helped carry out the trials, said: "We are very excited."
Type 1 diabetes develops when insulin-producing cells are destroyed, either by infection or the immune system attacking the pancreas which creates it.
Insulin helps cells convert glucose from food into energy.
Other autoimmune diseases include multiple sclerosis, Crohn's disease, rheumatoid arthritis and asthma.
Type 1 patients need daily insulin injections for life and must follow a strict diet regime. It often strikes in childhood, unlike Type 2, which usually occurs in adults when the body does not produce enough insulin or it does not work properly.
We are very excited
It is a chronic, life-threatening condition that is on the increase in the UK, particularly among the under-fives.
The latest trial of teplizumab, designed to block the advance of Type 1 in its earliest stages, has shown "striking" results over two years in about half of the patients who participated.
The trial results, published online in the journal Diabetes, show that the patients who benefited most were those who still had relatively good control of their blood sugar levels and only a moderate need for insulin injections. Most trial patients were under 14 years old and diagnosed within eight weeks of the start of the trials.
The patients who responded to teplizumab were able to maintain insulin production for the full two years of the trial.
Co-leader of the research Dr Jeffrey Bluestone, of the University of California, said the trials showed the importance of diagnosing and treating diabetes in its earliest stages.
The incidence of Type 1 diabetes is increasing and the age of onset is decreasing.
About 370,000 Britons have the disease.

subset: commoncrawl


text:
Groupers of the World: A Field and Market Guide, is a new book providing detailed and up to date information on all grouper species.
Groupers are a commercially important family of tropical fish found globally on coral and rocky reefs. The book contains more than 350 colour photographs of both dead and live animals that will aid the identification of these large and colourful fish in all situations.
"Identification is essential for monitoring fisheries and assessing species in the field," says Dr Matthew Craig, Co-chair, IUCN Species Survival Commission (SSC) Groupers and Wrasses Specialist Group. "This book is invaluable to scientists, divers and fish enthusiasts alike."
Groupers are an important source of food and income to many people. Vulnerable to over-fishing, 13% of all grouper species are considered to be threatened globally according to the criteria and categories of the IUCN Red List of Threatened Species™. Groupers are especially vulnerable to over-fishing because the large mating groups they form, known as aggregations, are easily targeted by fisheries. Some species that once gathered in groups of thousands or even tens of thousands are now classed as Endangered, mainly because of uncontrolled fishing on mating aggregations.
"The formation of mating aggregations, long sexual maturation time and a sex change in some species make many groupers particularly vulnerable to intensive commercial fishing," says Dr. Yvonne Sadovy, Co-chair, IUCN SSC Groupers and Wrasses Specialist Group. "Many aggregations are now fished commercially without regulation so better protection and management is required urgently."
The IUCN SSC Groupers and Wrasses Specialist Group has supported plans for the protection of groupers and mating aggregations. Through its membership, its work has contributed to understanding, conserving and managing groupers in many countries including The Bahamas, Belize, Fiji, Palau, Philippines and USA.
Groupers of the World: A Field and Market Guide will help the future conservation of groupers as it provides detailed up to date information on their biology with important ecological and population information as well as an assessment of their conservation status and distribution maps. This information can be used by fisheries managers and conservationists to develop and implement conservation action to better protect groupers across the world.
Groupers of the World: A Field and Market Guide is available directly from NISC.


text:
Spanish Prime Minister Jose Maria Aznar is to arrive in Tehran this weekend on a two-day official visit, the first by a Spanish government leader since the 1979 Islamic revolution in Iran, a Spanish diplomat said Thursday.
Aznar, who will be accompanied a delegation that includes 80 businessmen, will be traveling from Seoul, where he is to attend the Asia-Europe Meeting of heads of state.
During his visit, which will include a meeting with Iranian President Mohammad Khatami and a visit to the city of Isfahan, Aznar will discuss political issues, as well as economic, trade and cultural cooperation.
On the political front, there will be the chance for an "open dialogue" on tensions in the Middle East, the diplomat said. Madrid has long pushed for a resolution to the Palestinian question, while Tehran, which does not recognize Israel, totally opposed to the peace process, the diplomat said.
The diplomat was non-comittal when asked whether Aznar will raise the question of three Israeli soldiers captured by Iranian-backed Hizbollah guerrillas in Lebanon earlier this month.
On Oct 8, a day after the incident, Spanish Foreign Minister Josep Pique said the United States had asked Spain and France to intervene with Iran on behalf of the three soldiers.
Pique said the request had come from US Secretary of State Madeleine Albright, who said she hoped Paris and Madrid would ask Iran to act as a mediator with representatives of Hizbollah in an effort to free the soldiers.
Meanwhile, on the cultural front, Aznar will inaugurate an exposition of 100 engravings by the late 20th century Spanish artist, Joan Miro.
He will also give the opening address at a seminar on economic issues.
Spain is Irans's fourth-largest trading partner, though trade dropped from 1.07 billion dollars in 1997 to only 768 million last year, 70 percent of which was Spanish purchases of Iranian oil.
A number of Spanish banks are active in Iran, as well as nearly a dozen industrial firms.
Spain's principal exports to Iran are machine tools, chemical products, steel and automobiles – TEHRAN (AFP)
© 2000 Al Bawaba (www.albawaba.com [1])
[1] http://www.albawaba.com


text:
A Solid Foundation For Growth And Success
Kenneth T. Derr, Chairman of the Board and Chief Executive Officer
Chevron Corporation
Annual Meeting of Stockholders
San Francisco, California
It's always a pleasure to see so many of our stockholders at our annual meeting. Last year, we met in Houston and I know that many of you were unable to attend that meeting. So a special welcome to you this morning.
The first thing that I'd like to do is bring you up to date on the progress we've made toward our key financial goal. That goal is to provide you a total stockholder return that's higher than any of our key competitors for the five years -- 1994 through 1998. It's a tough goal. I'm sure that many of you recall that for the previous five years -- 1989 through 1993 -- Chevron was No. 1 among major oil companies, with a stockholder return of 18.9 percent -- five percentage points ahead of the average of our key competitors.
We know that repeating in that No. 1 spot for the current five-year period will be very difficult. But we're determined to do it.
Our annualized rate from the first of 1994 through the end of April was nearly 18 percent. That's a strong return, but it only puts us in a tie for fourth place among our leading competitors. That's not where we want to be, and I'm confident that we will improve on that position over the next two-and-a-half years.
Overall, our 1995 financial results were encouraging.
Our operating earnings were up 17 percent to nearly $2 billion. "Operating earnings" are an important measure of performance because they show income without the effect of any special items or accounting adjustments. There was a significant special item in 1995 -- a new accounting standard that reduced our earnings by $659 million.
Apart from this, the other large special item was a $168 million after-tax write-down of our real estate development business. The decision to sell the Chevron Land and Development Company fits with our strategic intent of concentrating efforts on our core businesses. Altogether, the special items brought reported earnings down to $930 million, or $1.43 a share.
Most of our businesses had an excellent year. Our international exploration and production company posted record earnings, and our chemicals business had the highest operating earnings in its history. Our U.S. exploration and production company also performed well in spite of low natural gas prices through most of the year.
On the other hand, output from our U.S. refining operations was curtailed by some planned and some unplanned maintenance shutdowns at our refineries. In addition, we had an extended period of downtime at the Richmond Refinery as we tied in new units to make the new cleaner-burning gasolines mandated by the state of California.
Cost control is an important factor in Chevron's financial performance. Over the past five years, we've cut more than $1.5 billion from our cost structure, including nearly $300 million last year.
In the global business climate of the 90s, cost control can no longer be viewed as something that gives you an edge over the competition. It's now a competitive necessity. One of the most impressive -- and most important --accomplishments of 1995 was the remarkable improvement in Chevron's safety performance.
Our goal is to have the best safety record among our key competitors. During the past two years, we've cut our rate of recordable incidents nearly in half. Not only does this save money, but -- more important -- it also reduces the pain and suffering of personal injuries This shows that when our employees focus on an important goal, they can make things happen.
1995 was an outstanding year for adding new oil and natural gas reserves. Overall, Chevron replaced 138 percent of our oil and gas production with new proved reserves. As a reflection of our emphasis on growth outside the U.S., the international replacement rate was an impressive 178 percent. The rate for the U.S. -- where it has become increasingly difficult for the petroleum industry to operate -- was a very respectable 92 percent.
Overall, our worldwide net crude oil production reached 1 million barrels a day.
At the end of the year, Chevron's worldwide proved reserves stood at 6 billion barrels of oil and equivalent gas. More than 700 million barrels were added to reserves, with more than 50 percent coming from new drilling.
Now, let's look at our first quarter 1996 results, which were excellent both operationally and financially.
Our net income was up $616 million or 94 cents a share -- a 34 percent increase over last year's first quarter. And our operating earnings were up an impressive 56 percent over the first quarter of 1995.
Worldwide exploration and production earnings benefited from strong crude oil and U.S. natural gas prices. At $519 million, they were up 61 percent over last year's first quarter. Our worldwide refining and marketing earnings also improved over last year. In particular, our U.S. operations showed a big improvement -- earning $18 million compared with a loss of $102 million last year.
Here, higher crude oil prices hurt us. Our product prices could not keep up with the higher costs -- not only of crude oil, but also of the added cost of making the new and cleaner-burning California gasolines.
As expected -- our chemical earnings dropped. This is the outcome of softer industry conditions and higher feedstock costs.
Chevron's story isn't reflected just in numbers. These figures don't tell the whole story. On their own, they don't say what I strongly believe . . . that 1995 was a breakthrough year for our company.
Although -- as I mentioned earlier -- cost control continues to be a vital part of Chevron's strategy, we're excited about the opportunities for growth. And we're backing our optimism with an increased capital and exploratory budget. This year it's set at $5.3 billion -- a 10 percent increase over 1995.
About $3 billion of that is earmarked for worldwide exploration and production projects. Again, a 10 percent increase over last year. About 65 percent of that -- or more than $2 billion -- will be spent on international projects. We also feel that there are excellent prospects in the U.S., and we plan to increase U.S. exploration and production spending by about 20 percent to more than $1 billion.
We're increasing the budget for our worldwide chemicals business -- more than doubling it to about $500 million.
On the other hand, we're reducing the budget for worldwide refining, marketing and transportation by more than $250 million.
The optimism that is driving this budget is rooted firmly in Chevron's past performance because it has created a strong foundation that will provide for growth and future success. We are a stronger company now than ever before.
For instance, many of the major projects we've invested in over the years are beginning to provide significant cash flow and earnings.
We have honed our holdings -- divesting many non-strategic assets -- to create a stronger-than-ever portfolio.
Chevron also is well-known -- and well-respected -- for our strength in science and technology . . . our leadership on environmental issues . . . and our efforts to ensure that, wherever we operate, our neighbors benefit from our activities. These not only have contributed to our worldwide success, but also are the reasons Chevron often is the partner of choice in international joint ventures.
You've all received Chevron's 1995 Annual Report. If not or if you'd like an additional copy, they're available in the registration area. Our theme this year is "New Prospects. New Perspectives."
This year, we have a lot of new -- and exciting -- prospects and in a few minutes, Vice Chairman Jim Sullivan will describe many of them.
"New Perspectives" is a little harder to explain, but may be even more important. We're looking at our business in new ways . . . from a fresh perspective. In today's highly competitive global economy, you have to find new and better ways to run your business . . . or you don't survive. It's as simple as that.
Chevron definitely has new perspectives. We're more entrepreneurial -- as a company and as individual employees. One of the more important strengths of this company is its employees. When I say Chevron has changed and has a new perspective, I don't mean that an abstract, monolithic corporation is now different. What I really mean is that individual employees and small work teams are viewing their jobs differently and are working in new and better ways.
- It was a new perspective that produced our innovative alliance with McDonald's.
- It was looking at our usual businesses in an unusual way that led to the proposed merger of our U.S. natural gas and gas liquids businesses with the NGC Corporation. This is an extremely complex merger that will give Chevron 28 percent of a new company that will be North America's largest processor and marketer of natural gas and natural gas liquids.
- It was taking a different perspective that allowed us to negotiate a new -- and unusual -- joint venture with Venezuela. This is the first time that Chevron's production, and refining and marketing businesses have joined together in an alliance with another country.
Now, I'd like to turn the meeting over to our Vice Chairman, Jim Sullivan for a closer look at many of Chevron's operations.
Mr. Sullivan speaks. Mr. Derr returns to podium.
Thank you, Jim.
Both Jim and I mentioned our innovative new venture in Venezuela. I've just returned from Caracas and Maracaibo, where we dedicated our new Chevron office and signed an agreement to consider expanding our alliance. I came back feeling very good about our prospects there.
But that feeling didn't last too long. I returned to find the petroleum industry under attack -- accused of everything from manipulating supplies to price gouging. The public and political reactions to rising gas prices were immediate and based on a several inaccurate conclusions.
One of the most fundamental misconceptions is that improved first quarter earnings and higher gas prices are proof of "price gouging."
In fact, in the first quarter, our U.S. refining and marketing earnings were just $18 million on capital of $6 billion. Although that was a big improvement over the $100 million loss of the previous year's first quarter, it was a rather disappointing return on capital of about 1 percent. Not what I'd call "price gouging."
Now let's look at some of the real reasons that gasoline prices have gone up. Basically, there are four main factors driving higher gasoline prices. And, unfortunately for the consumer, they converged in April.
- Let's start with the one that is the basis of our free-market economy . . . supply and demand. Right now, supply is tight . . . and for a variety of reasons. An especially cold and long winter kept refineries busy making heating oil and diesel longer than usual. Then, in California, we had several refinery breakdowns. None were ours, I'm happy to say. Demand, on the other hand, is growing around the world. In the U.S. -- as reported in Sunday's New York Times -- people are driving more miles each year, the average use of gasoline is rising . . . and average gasoline mileage is declining.
- Second -- until recently, crude oil prices have been rising. Since early February, they're gone up as much as $7.50 a barrel -- or 19 cents a gallon. The increase was caused by higher demand triggered by the cold weather and by the uncertainty over when the United Nations might lift the Iraqi oil embargo.
- In California, another contributing factor is the state's new reformulated gasoline, which adds 5 to 15 cents a gallon to manufacturing costs. This gasoline is clearly one of the best ways to reduce air pollution. It's the cleanest burning gasoline in the world, delivering a 15 percent reduction in smog-forming emissions.
- The fourth factor -- taxes. They account for roughly one-third of the pump price. In California, taxes add about 49 cents a gallon. And because sales taxes are applied to the pump prices, they've added another 2 to 3 cents a gallon since February first.
So -- we're not looking at a major mystery . . . or a conspiracy . . . or price gouging. We're looking at four separate, but understandable, events that came together and sent prices up -- the combination of short supply and increased demand, higher crude oil prices, higher manufacturing costs and higher taxes.
The U.S. Department of Energy and the Department of Justice say they plan to investigate. This happens every time there's a price spike -- especially one that comes in an election year. A recent New York Times columnist pointed out that a fuss over gasoline prices is -- as he put it -- "part of the American political tradition."
The results of these prior investigations always have been the same. They show that there was no price gouging. Just the marketplace in action.
When the emotional element is removed, gasoline is a fairly cheap commodity. Over the past few years, prices -- when adjusted for inflation -- have been as low as any time since World War II. In 1981, the average price was $1.38 a gallon. If prices had kept pace with inflation just since 1981, gasoline now would cost more than $2.25 a gallon.
These currently higher prices are not likely to last. The marketplace ultimately will correct the imbalance. Crude oil prices are starting to decline, and the price of gasoline should follow when inventories rebuild to normal levels.
Jim -- in his tour of the world -- described many of the reasons why I'm so optimistic about Chevron's future.
A key part of that future . . . or maybe I should say -- the key to the future is Chevron's committed team of employees.
One of the many positive outcomes of our restructurings has been a fresh view of the employee and what he or she can do when empowered and given the authority to make decisions.
We must not overlook the fact that today's jobs are more challenging and -- we hope -- more interesting. Chevron is a flatter organization. There are fewer layers of management and fewer people who spend their time checking and double-checking the work of others. We've delegated more authority -- and with it -- more responsibility to the people doing the work.
In short -- we're asking more of our people. . . . And they're asking more of themselves. Employee commitment is so important to Chevron that one of the eight strategic intents guiding the company states that we should -- "Build a committed team to accomplish the corporate Mission." And the first item in our corporate Vision says that we want employees to be proud of their success as a team.
I'd like to tell all of Chevron's employees that I'm proud of them. I'd also like to thank them for jobs well done. Everything we've talked about this morning -- from record earnings to added reserves to improved safety records -- was accomplished through the hard work of Chevron's employees. My thanks to each of them.
Now -- this is a good time to introduce you to a few of Chevron's most committed and most outstanding employees -- people who can be proud of their successes. These are the employees whose outstanding individual or team efforts recently have earned them the Chairman's Award. I'd like them all to stand. They deserve our praise and a generous round of applause. Once again, thank you all for jobs well done.
Over the past few years we've created several documents to define and guide the company. Last year, we put these all together into one document that we call "The Chevron Way."
In truth, it's really more than a document. In a few pages, this booklet states our Mission and Vision and outlines our values and beliefs. "The Chevron Way" sums up -- not only what Chevron is and what it does -- but also what we stand for and what we believe in.
I hope you'll pick up a copy of it as you leave this morning.
All of us in Chevron, appreciate your attendance here today, and we look forward to seeing you at future Annual Meetings.
Updated: May 1996


text: I have noticed none of my 6 Raven Shield game servers appear on the multiplayer server list. Yesterday I couldn't login to my UBI account to play in any server and then today I am able to login and none of my servers show up. I can connect to each of them through IP under LAN. Makes no sense to me what so ever, thought maybe someone else has had this happen to them before. I can't see it being my servers cause I have 2 of them through Defcon and 4 through Devil Dogs.


text:
HMRC have provided a range of special schemes that apply to smaller businesses. They are designed to reduce administration, but also (in some cases) to assist cash flow.
Tax & Accounting Guides
Key Guides
- The Key Business TaxesWhich taxes you will encounter as a small business owner
- Top 10 Tax TipsSome no-nonsense pointers from the Bytestart team
- National InsuranceWhich NICs are you liable for as a small business owner?
- Corporation TaxHow limited companies are taxed
- Dividend TaxHow much tax do you have to pay on limited company dividends?
- Entrepreneurs' ReliefA rare tax concession if you decide to sell your business
- Capital AllowancesTax relief if you buy equipment or invest in R&D
- Business ExpensesWhat can you legitimately claim against your business income?
- Sole Trader TaxSole traders are liable to income tax and NICs on their business income
- Guide to PAYEHow the Paye As You Earn scheme operates
- Business Stamp DutyHow Stamp Duty applies to premises or share transactions
- Business RatesHow Rates are applied to business premises
- Home Office ExpensesWhat can you claim against your business income?
- HMRC PenaltiesOverview of the new HMRC penalties regime
Our Main Tax Guides
- Summary of key tax rates, thresholds and allowances for business owners for 2014/15
- Tax Rates for small business owners 2013/14
- Small business accountants10 tips for choosing the right accountant for your business
- Book Keeping BasicsThe fundamentals of how to keep accurate business records
- HMRC Payroll FormsWhat do the main forms do – including P45,P60 and P11D
- Profit & Loss GuideSummary of what you've bought and sold over 12 months
- What is a Balance Sheet?A snapshot of the financial health of your business
- Book Keeping TipsHelpful advice to keep your business books in order
- Value Added TaxAn overview of VAT, and how the tax is collected
- How to Register for VATYou must register if you turnover reaches the VAT threshold
- VAT Cash AccountingYou account for VAT when income is received, rather than by invoice date
- Flat Rate VAT SchemeCreated to simplify the VAT calculations for eligible small businesses
Tax Rates
Book Keeping / Accounts
Value Added Tax Guides


text:
OTTAWA - If Daniel Alfredsson had his druthers, every NHL season would be 50 games long.
"Not just because I'm older," said the Senators captain, who turned 40 last month. "It would make for better hockey, a better product overall, I guess.
"For me, selfishly, it's not a bad thing."
Coach Paul MacLean will decide if the team's eldest statesman should even play that many. While Alfredsson says his back is good now, the busy schedule could take its toll on him and other veterans.


text:
Practical Application of PRMS (Petroleum Resources Management System)
This course allows an overview and in-depth look at the framework, classifications and applications of SPE's Petroleum Resources Management System (PRMS). Participants will gain a solid understanding of this valuable resource management tool.
Topics Include:
- Defining the project and evaluating risk and uncertainty
- Incremental projects and unconventional resources
- Entitlement and recognition
- Review of resource assessment methods
- The resource management processes
- Integrating internal and external reporting
At the end of this course, participants should have an understanding of:
- Resource tracking and reconciliations
- Special classification and categorization issues
- Hybrid deterministic and probabilistic methods–class exercise
- Quality assurance and quality control
- Coordinating international standards
Learning Level
Course Length
2 Days
Why Attend?
PRMS is a powerful management tool that is widely used in the industry. If your job includes any aspect of resource management, this course will enhance your skills.
Who Should Attend
This course is for anyone who works closely with the generating and reporting of reserves, and for those who make resource estimates for business decisions.
1.6 CEUs (Continuing Education Units) awarded for this 2-day course.
Cancellation Policy
All cancellations must be received no later than 14 days prior to the course start date. Cancellations made after the 14 day window will not be refunded. Refunds will not be given due to no show situations.
Training sessions attached to SPE conferences and workshops follow the cancellation policies stated on the event information page. Please check that page for specific cancellation information.
SPE reserves the right to cancel or re-schedule courses at will. Notification of changes will be made as quickly as possible; please keep this in mind when arranging travel, as SPE is not responsible for any fees charged for cancelling or changing travel arrangements.
We reserve the right to substitute course instructors as necessary.
Full Regional cancellation policies can be found at the "Cancellation Policy" link on the SPE Training Course Catalog page: http://www.spe.org/training/catalog.php.
John Etherington is managing director of PRA International Ltd., a Calgary-based consulting firm advising industry on resources assessment and reporting since 2000. Etherington holds BS and PhD degrees in geology. He previously spent more than 32 years with Mobil Oil in Canada, the US, and international assignments. Etherington served on the SPE Oil and Gas Reserves Committee with primary responsibility for the 2007 PRMS project. He also coordinated SPE's interface with the United Nations Framework Classification and the International Accounting Standards Board's Extractive Activities projects. He was an SPE Distinguished Lecturer in 2005–2006, has presented papers on resources evaluation issues at AAPG, EAGE, and SPE conferences, and has conducted training for more than 1200 geoscientists and engineers from 46 countries.


text: FRANCOFORTE, 15 aprile (Reuters) - The European Central Bank announced the following results for its latest liquidity providing operation: Main Refinancing Operation-Allotment Intended Volume: Reference Number: 20140081 Min Allotment: Transaction Type: Reverse Transactions Fixed Rate: 0.25 % Operation Type: Liquidity Providing Max Bid Limit: Procedure: Standard Tender Max Bids per Cpty: 1 Tender Date: 15/04/2014 11:15 Marg. Rate: Start Date: 16/04/2014 % of All. at Fixed Rate: 100 Maturity Date: 23/04/2014 Tot Amount Allotted: 112165.1 mn Duration (days): 7 Weight. Avg. Allot. Rate: Tot Bid Amount: 112165.1 mn Auction Type: Fixed Rate Tender Tot Number of Bidders: 172 Allotment Method: Min Rate (bids): Max Rate (bids): Estimate on 15/04/2014 of the average autonomous factors for the period 14/04/2014 to 22/04/2014 amounts to EUR 472.6 bn. Benchmark allotment based on the ECB's liquidity forecast as at 15/04/2014 amounts to EUR 83.0 bn. For general information on the calculation of the benchmark allotment amount, please see www.ecb.europa.eu/mopo/liq/html/index.en.html as well as ECB page Operational Communications.


text:
- 83 Downloads
- Citations
Acarbose delays digestion of complex carbohydrates and disaccharides to absorbable monosaccharides, by reversibly inhibiting α-glucosidases within the intestinal brush border, thereby attenuating postprandial blood glucose peaks.
Clinical trials have demonstrated that acarbose generally improves glycaemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) managed with diet alone, or with other antidiabetic therapy, as evidenced by decreased postprandial plasma glucose and glycosylated haemoglobin levels. It does not appear to directly alter insulin resistance, but may lower postprandial plasma insulin levels. Fasting plasma glucose, triglyceride and/or cholesterol levels may also be decreased. Acarbose also improved metabolic control in patients with insulin-dependent diabetes mellitus (IDDM), frequently decreasing insulin requirements, although further studies are required in this indication.
Improved metabolic control appears to delay or prevent long term vascular complications of diabetes, and indeed, acarbose appeared to inhibit development of such complications in preliminary animal studies, but this finding requires confirmation in clinical studies.
While acarbose seldom causes systemic adverse effects, it is associated with a high incidence of gastrointestinal disturbances such as flatulence, abdominal distension, borborygmus and diarrhoea, caused by fermentation of unabsorbed carbohydrates. However, these symptoms tend to subside with continued treatment and adherence to an appropriate diet.
Thus, acarbose appears to be a worthwhile adjunctive therapeutic option for patients with NIDDM inadequately managed by diet alone, or with pharmacological therapy, and possibly also for patients with IDDM. However, further long term efficacy and tolerability data are required, particularly in the latter indication.
Pharmacological Properties
Acarbose is an oligosaccharide which reversibly inhibits intestinal α-glucosidase enzymes responsible for digestion of complex carbohydrates and disaccharides to absorbable monosaccharides. Thus, acarbose delays postprandial absorption of glucose, resulting in attenuation of postprandial plasma glucose, insulin and triglyceride peaks in healthy volunteers. The beneficial effects of acarbose on postprandial glucose levels have been confirmed in patients with insulin-dependent or non-insulin-dependent diabetes mellitus (IDDM or NIDDM), whereas postprandial insulin and triglyceride levels were only occasionally lowered. Pooled data from several clinical trials indicate that acarbose lowers postprandial and fasting blood glucose levels in patients with NIDDM by approximately 20 and 10%, respectively, the latter presumably by an indirect mechanism. Acarbose does not appear to exert any direct effect on insulin resistance in humans.
By decreasing the hyperglycaemic stimulus to insulin secretion, acarbose attenuates the blood glucose nadir and associated clinical symptoms which occur after carbohydrate ingestion in patients with reactive hypoglycaemia.
Delayed carbohydrate digestion increases the amount of fermentable carbohydrate in the bowel, which does not appear to cause calorie loss, because of metabolism to other absorbable nutrients by colonic microflora, but can induce gastrointestinal adverse effects such as flatulence and borborygmi. Acarbose decreases the postprandial gastric inhibitory polypeptide response, while increasing the enteroglucagon response, and also decreases intestinal absorption of iron. It does not generally appear to lower bodyweight in humans, although this effect has consistently been demonstrated in animal models.
Acarbose decreases serum triglycerides, cholesterol and free fatty acid levels in animal models of diabetes and/or hyperlipidaemia, but in human studies in diabetic and nondiabetic individuals, does not consistently lower fasting plasma triglycerides and produces only occasional decreases in fasting plasma cholesterol.
The Diabetes Control and Complications Trial (DCCT) has demonstrated that optimal control of blood glucose levels can retard long term complications of diabetes. Indeed, acarbose decreases levels of glycosylated haemoglobin in patients with diabetes, and glycosylation of other body proteins in preliminary animal studies. Moreover, acarbose appeared to inhibit development of renal, cardiovascular, retinal, and neurological complications in various animal models of diabetes and/or hyperlipidaemia. The latter findings await confirmation in clinical studies.
Consistent with its intestinal site of action, acarbose is minimally (<2%) absorbed in unchanged form following oral administration to healthy volunteers. However, it is rapidly and extensively metabolised by intestinal digestive enzymes, and absorption of metabolites formed in the gut yields a biphasic pattern of absorption in studies with radiolabelled acarbose, with separate peaks at 1 to 2 and 6 to 24 hours. Administration of acarbose 300mg 3 times daily for 90 days to healthy volunteers did not result in accumulation.
Acarbose has a small volume of distribution (0.32 L/kg) and was minimally bound to animal plasma proteins at concentrations ≥ 1 μg/L, and 98% bound at 0.008 μg/L. Acarbose and/or its metabolites were secreted into breast milk and penetrated across the placental barrier in rats.
Approximately 35% of an orally administered dose of acarbose is excreted in the urine, virtually all in metabolised form, and approximately 50% in the faeces. The total body clearance of acarbose was around 600 L/h and values of up to 39.5 hours have been reported for the terminal elimination half-life.
Therapeutic Use
In noncomparative and placebo-controlled studies of 2 to 12 months' duration, acarbose generally improved metabolic control in patients with NIDDM, whether used with diet alone, or with other antidiabetic agents, including sulphonylureas, biguanides or insulin. Postprandial plasma glucose levels were lowered by approximately 2 to 3 mmol/L and glycosylated haemoglobin levels were also decreased. Fasting plasma glucose and triglyceride levels, and insulin requirements, were also occasionally decreased. Acarbose was not effective in some patients, possibly reflecting low dosages used and/or severe carbohydrate restrictions in some instances, or lack of sensitivity of intestinal α-amylases to acarbose.
Acarbose tended to be slightly less effective than sulphonylureas and biguanides, particularly with regard to effects on fasting plasma glucose, but was at least as effective as guar gum in 1 study.
Acarbose has been less well studied in patients with IDDM, but improved glycaemic control, as evidenced by improved daily blood glucose profiles and decreased glycosylated haemoglobin levels, and frequently, decreased insulin requirements. It may also lower the risk of late hypoglycaemic episodes (those occurring several hours after a meal) in patients with IDDM.
Data from preliminary studies indicated that acarbose might be useful in patients with reactive hypoglycaemia, dumping syndrome and types IIb or IV hyperlipidaemia, but to date no large-scale studies appear to have been performed in these indications.
Gastrointestinal disturbances such as flatulence, abdominal distension, diarrhoea and borborygmus, caused by fermentation of unabsorbed carbohydrate in the bowel, are the most common adverse effects associated with acarbose therapy and may occur in up to two-thirds of patients. These symptoms generally improve with continued treatment, and may be minimised by initiating therapy at a low dosage and adherence to diet. The tolerability of acarbose in children aged 5 to 16 years is similar to that in adults.
Systemic adverse effects are rare during acarbose therapy. However, analysis of data from phase III US studies indicated that anaemia and elevated transaminase levels were significantly more common in acarbose, than in placebo recipients, occurring in 3.8 and 1.1% of patients, respectively.
Acarbose was reported to decrease both peak concentrations and area under the concentration-time curve of metformin by 35% when the 2 drugs were given concurrently to healthy volunteers.
Dosage and Administration
The recommended starting dose of acarbose for patients with NIDDM is 50mg 3 times daily, taken before meals, which may be increased to 100mg 3 times daily after 6 to 8 weeks if necessary, and subsequently to a maximum of 200mg 3 times daily if required. Dosages used in patients with IDDM in clinical trials were similar to those used in NIDDM. Patients receiving the maximum dose should be monitored closely for elevation of serum transaminase levels, preferably at monthly intervals, for the first 6 months of treatment. Contraindications to acarbose use include inflammatory bowel disease, partial intestinal obstruction or predisposition to intestinal obstruction, chronic intestinal disease associated with marked disorders of absorption or digestion, conditions which might be exacerbated by increased intestinal gas formation (such as hernias), and impaired hepatic function. Additionally, acarbose has not been studied in patients with severe renal impairment.
As acarbose may potentiate the hypoglycaemic effects of insulin and sulphonylureas, dosages of these agents may require adjustment when acarbose is administered concurrently. If hypoglycaemia occurs, patients should take glucose rather than carbohydrate foods. The effects of acarbose may be reduced by concomitant administration of intestinal adsorbents such as charcoal, and digestive enzyme preparations such as amylase or pancreatin, and enhanced by concomitant administration of neomycin or cholestyramine.
Unable to display preview. Download preview PDF.
- Ahr HJ, Boberg M, Krause HP, Maul W, Müller FO, et al. Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C] acarbose to rats, dogs and man. Arzneimittel-Forschung 39: 1254–1260, 1989aPubMedGoogle Scholar
- Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H. Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C] acarbose to rats and dogs. Arzneimittel-Forschung 39: 1261–1267, 1989bPubMedGoogle Scholar
- Anon. Acarbose prescribing information, UK, 1993Google Scholar
- Austenat E. Recent therapy studies with acarbose in type I diabetics. Endokrinologie und Stoffwechsel 12: 19–24, 1991Google Scholar
- Akazawa Y, Koide M, Oishi M, Azuma T, Tashiro S. Clinical usefulness of acarbose and fiber in the treatment of diabetes mellitus. Therapeutics 36: 848–849, 870-875, 1982Google Scholar
- Aubell R, Boehme K, Berchtold P. One-year acarbose treatment of diabetic out-patients. Multicentre study part II: efficacy. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 363–366, Excerpta Medica, Amsterdam, 1982Google Scholar
- Axen KV, Sclafani A. Acarbose decreases insulin resistance in a rat model of NIDDM. Diabetes 39 (Suppl. 1): 49A, 1990 (abstract)Google Scholar
- Bartram H-P, Scheppach W, Heid C, Fabian C, Kasper H. Effect of starch malabsorption on fecal bile acids and neutral sterols in humans: possible implications for colonic carcinogenesis. Cancer Research 51: 4238–4242, 1991PubMedGoogle Scholar
- Boberg M, Kurz J, Ploschke HJ, Schmitt P, Scholl H, et al. Isolation and structural elucidation of biotransformation products from acarbose. Arzneimittel-Forschung 40: 555–563, 1990PubMedGoogle Scholar
- Buchanan DR, Collier A, Rodrigues E, Millar AM, Gray RS, et al. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes. European Journal of Clinical Pharmacology 34: 51–53, 1988PubMedCrossRefGoogle Scholar
- Chakrabarti S, Cherian PV, Sima A. The effect of acarbose on diabetes- and age-related basement membrane thickening in retinal capillaries of the BB/W rat. Diabetes Research and Clinical Practice 20: 123–128, 1993PubMedCrossRefGoogle Scholar
- Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. The effectiveness of acarbose in the treatment of patients with NIDDM. A multi-centre Canadian trial. Submitted for publication 1993.Google Scholar
- Chisholm DJ. Diabetes Monitoring; use of glycated haemoglobin and glycated protein assays. Australian Prescriber 14: 59–61, 1991Google Scholar
- Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 35: 214–243, 1988PubMedCrossRefGoogle Scholar
- Cohen MP, Klepser H. Alpha-glucosidase inhibition prevents increased collagen fluorescence in experimental diabetes. General Pharmacology 22: 607–610, 1991PubMedCrossRefGoogle Scholar
- Cohen AM, Rosenmann E. Acarbose treatment and diabetic nephropathy in the Cohen diabetic rat. Hormone and Metabolic Research 22: 511–515, 1990PubMedCrossRefGoogle Scholar
- Cohen MP, Klepser H, Wu V-Y. Effect of alpha-glucosidase inhibition on the nonenzymatic glycation of glomerular basement membrane. General Pharmacology 22: 515–519, 1991PubMedCrossRefGoogle Scholar
- Coniff RF, Innerfield RJ. A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (Bay g 5421) and SFU in the Rx of NIDDM inadequately controlled by maximal SFU. Abstract. Diabetes 39 (Suppl. 1): 109A, 1990Google Scholar
- Couet C, Ulmer M, Hamdaoui M, Bau HM, Debry G. Metabolic effects of acarbose in young healthy men. European Journal of Clinical Nutrition 43: 187–196, 1989PubMedGoogle Scholar
- Decarr LB, Velazquez N, Vasselli JR. Acarbose reduces nonenzymatic glycation of low density lipoprotein (GLDL) and improves lipoprotein composition in sucrose-fed diabetic rats. Abstract. Diabetes 40 (Suppl. 1): 270, 1991Google Scholar
- DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–194, 1991PubMedCrossRefGoogle Scholar
- Deege J, Chantelau E. Alpha-glukosidase inhibition attenuates postprandial plasma glucose response to Coca-Cola™ during insulin-induced hypoglycaemia. In German. Aktuelle Endokrinologie und Stoffwechsel 11: 198–202, 1990Google Scholar
- de Leiva A, Piñón P, Tébar J, Escobar-Jimánez F, de Leiva A, de la Calle H, et al. Efficacia clínica y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos no dependientes de la insulina (tipo II). Med Clin (Barcelona) 100: 368–371, 1993Google Scholar
- Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329: 977–986, 1993CrossRefGoogle Scholar
- Dimitriadis G, Hatziagellaki E, Alexopoulos E, Kordonouri O, Komesidou V, et al. Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type 1 diabetes mellitus. Diabetes Care 14: 393–398, 1991PubMedCrossRefGoogle Scholar
- Drost H, Hillebrand I, Koschinsky T, Voegtle-Boehringer M, Gries FA. Double-blind cross-over studies on the influence of the glucosidase inhibitor acarbose in type II diabetics. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 330-334, Excerpta Medica, Amsterdam, 1982Google Scholar
- Ebert R, Zarth J, Jakob J, Creutzfeldt W. Gastric effects of acarbose in type 2 diabetics. European Journal of Clinical Investigation 23 (Suppl. 1): A43, 1993Google Scholar
- Escobar-Jiménez F, de Leiva A, Piñón P, Soler J, Tebar J, et al. Efficacia clínica y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos dependientes de la insulina (tipo 1). Medicina Clinica (Barcelona) 100: 488–491, 1993Google Scholar
- Friedman JE, de Venté JE, Peterson RG, Dohm GL. Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa). American Journal of Physiology 261: E782–E788, 1991PubMedGoogle Scholar
- Fölsch UR, Lembcke B, Ebert R, Caspary WF, Creutzfeldt W. Sucrose tolerance during treatment with acarbose and/or metronidazole. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 97–106, Exerpta Medica, Amsterdam, 1982Google Scholar
- Füessl HS, Adrian TE, Uttenthal LO, Bloom SR. Peptide YY in diabetics treated chronically with an intestinal glucosidase inhibitor. Klinische Wochenshrift 66: 985–989, 1988CrossRefGoogle Scholar
- Gérard J, Luyckx AS, Lefebvre PJ. Acarbose in reactive hypoglycaemia: a double-blind study. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 25–31, 1984aGoogle Scholar
- Gérard J, Lefèbvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. European Journal of Clinical Pharmacology 27: 233–236, 1984bPubMedCrossRefGoogle Scholar
- Gil E, Guardiola E. Efecto de la acarbosa sobre la glucemia y la secreción de hormonas pancreáticas inducida por comidas habituales en España. Revista Clinica Española 191: 416–421, 1992PubMedGoogle Scholar
- Gómez-Pérez FJ, Violante R, Sánchez-Arriaga LF, Wong B, Rull JA. Eficacia y tolerancia de acarbose en pacientes diabéticos no dependientes de insulina. Revista de Investigacíon Clinica 44: 77–83, 1992PubMedGoogle Scholar
- Goto Y, Toyoda T, Oikawa S, Moruhama Y, Tamura M, et al. Long-term administration of BAY g 5421 (acarbose) in NIDDM [Translated into English from Japanese.] Yakuri to Chiryo 17: 387–401, 1989aGoogle Scholar
- Goto Y, Nakagawa S, Goto Y, Ikeda Y, Hosoya N, et al. Utility of BAY g 5421 (acarbose) on NIDDM, multicentre open study [Translated into English from Japanese.] Kiso to Rinsho 23: 219–239, 1989bGoogle Scholar
- Goto Y, Nakagawa S, Goto Y, Hosoya Y, Orishige H et al. Clinical utility of BAY g 5421 (acarbose) on NIDDM. Multicentre double-blind comparative study [Translated into English from Japanese.] Igaku no Ayumi 149: 591–618, 1989cGoogle Scholar
- Groop P-H, Groop L, Toetterman KJ, Fyhrquist F. Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinologica 112: 361–366, 1986PubMedGoogle Scholar
- Groot PHE, van Stiphout WAH, Krauss XH, Jansen H, van Tol A, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arteriosclerosis and Thrombosis 11: 653–662, 1991PubMedCrossRefGoogle Scholar
- Hamada H, Iida R, Mitsuzono T. Effects of acarbose in combination with tolbutamide or insulin on normal and diabetic rats. In Japanese. Yakuri to Chiryo 17: 29–44, 1989aGoogle Scholar
- Hamada H, Iida R, Ishimura K. Effect of acarbose on diabetes in KK mice. In Japanese. Yakuri to Chiryo 17: 17–25, 1989bGoogle Scholar
- Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14: 732–737, 1991PubMedCrossRefGoogle Scholar
- Hasche H, Ulm K, Mehnert H. Ambulant additive therapy with acarbose by badly regulated NIDDs. Abstracts of the 12th Congress of the International Diabetes Federation, Madrid, September, 1985, p 227, Elsevier, Amsterdam, 1985Google Scholar
- Hayakawa T, Kondo T, Okumura N, Nagai K, Shibata T, et al. Enteroglucagon release in disaccharide malabsorption induced by intestinal α-glucosidase inhibition. American Journal of Gastroenterology 84: 523–526, 1989PubMedGoogle Scholar
- Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G. Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro. Digestive Diseases and Sciences 37: 1057–1064, 1992PubMedCrossRefGoogle Scholar
- Hillebrand I, Boehme K. Clinical studies on acarbose during 5 years. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 445–450, Excerpta Medica, Amsterdam, 1982Google Scholar
- Hillebrand I, Englert R. Efficacy and tolerability of a 12-week treatment with acarbose (BAY g 5421), miglitol (BAY m 1099) and glibenclamid. Diabetes 26: 134A, 1987Google Scholar
- Hillebrand I, Graefe KH, Bischoff H, Frank G, Raemsche KD, et al. Serum digoxin and propranolol levels during acarbose treatment. Diabetologia 21:282, 1981Google Scholar
- Hoffmann J. Acarbose and glibenclamid in type-II-diabetes. A comparative study on efficacy and side effects. In German. Münchener Medizinische Wochenschrift 132: 487–490, 1990Google Scholar
- Hollander P. Safety profile of acarbose, an a-glucosidase inhibitor. Drugs 44 (Suppl. 2): 47–53, 1992PubMedCrossRefGoogle Scholar
- Hollander P, Coniff RF. Two multicenter, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes. Diabetes 40 (Suppl. 1): 307A, 1991Google Scholar
- Hotta N, Kakuta H, Koh N, Sakakibara F, Haga T, et al. The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabetic Medicine 10: 355–358, 1993aPubMedCrossRefGoogle Scholar
- Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic Medicine 10: 134–138, 1993bPubMedCrossRefGoogle Scholar
- Innerfield RJ, Coniff RF. A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (Bay g 5421) in the Rx of obese patients with NIDDM Rxed by diet alone. Abstract. Diabetes 39 (Suppl. 1): 211A, 1990Google Scholar
- Jenkins DJA, Taylor RH. Acarbose: dosage and interaction with sugars, starch and fibre. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 86–96, Exerpta Medica, Amsterdam, 1982Google Scholar
- Jenkins DJA, Taylor RH, Goff DV, Fielden H, Misiewicz JJ, et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 30: 951–954, 1981PubMedCrossRefGoogle Scholar
- Jenkins DJA, Taylor RH, Nineham R, Goff DV, Bloom SR, et al. Manipulation of gut hormone response to food by soluble fiber and a-glucosidase inhibition. American Journal of Gastroenterology 83: 393–397, 1988PubMedGoogle Scholar
- Johansen K. Acarbose treatment of sulphonylurea-treated non-insulin dependent diabetics-a double-blind crossover comparison of an a-glucosidase inhibitor with metformin. Diabete et Metabolisme 10: 219–223, 1984PubMedGoogle Scholar
- Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? British Journal of Clinical Pharmacology 30: 391–396, 1990PubMedPubMedCentralCrossRefGoogle Scholar
- Katovich MJ, Meldrum MJ, Vasselli JR. Beneficial effects of dietary acarbose in the streptozotocin-induced diabetic rat. Metabolism 40: 1275–1282, 1991PubMedCrossRefGoogle Scholar
- Kritchevsky D, Tepper SA, Davidson LM, Klurfeld DM. Influence of acarbose (a glucosidase inhibitor) on experimental atherosclerosis in the rabbit. Artery 17: 170–175, 1990PubMedGoogle Scholar
- Ladas SD, Frydas A, Papadopoulos A, Raptis SA. Effects of α-glucosidase inhibitors on mouth to caecum transit time in humans. Gut 33: 1246–1248,1992PubMedPubMedCentralCrossRefGoogle Scholar
- Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ, Reaven GM. Acarbose treatment of non-insulin-dependent diabetes mellitus. Archives of Internal Medicine 144: 345–347, 1984PubMedCrossRefGoogle Scholar
- Lee SM. The effect of chronic alpha-glucosidase inhibition on diabetic nephropathy in the db/db mouse. Diabetes 31: 249–254, 1982PubMedCrossRefGoogle Scholar
- Le Marchand-Brustel Y, Rochet N, Grémeaux T, Marot I, van Obberghen E. Effect of an α-glycosidase inhibitor on experimentally-induced obesity in mice. Diabetologia 33: 24–30, 1990PubMedCrossRefGoogle Scholar
- Leonhardt W, Hanefeld M, Fischer S, Schulze J, Spengler M. Beneficial effects on serum lipids in noninsulin-dependent diabetics by acarbose treatment. Arzneimittel Forschung 41: 735–738, 1991PubMedGoogle Scholar
- Maggio CA, Vasselli JR. Satiety in the obese Zucker rat: effects of carbohydrate type and acarbose (Bay g 5421). Physiology and Behaviour 46: 557–560, 1989CrossRefGoogle Scholar
- Marena S, Tagliaferro V, Cavallero G, Pagani A, Montegrosso G, et al. Double-blind crossover study of acarbose in type 1 diabetic patients. Diabetic Medicine 8: 674–678, 1991PubMedCrossRefGoogle Scholar
- Maruhama Y, Goto Y. Clinical application of a glucoside-hydrolase inhibitor (Bay g 5421) to patients with hyperlipidemia and maturity onset type diabetes mellitus. Tohoku Journal of Experimental Medicine 130: 243–252, 1980CrossRefGoogle Scholar
- Maruhama Y, Nagasaki A, Kanazawa Y, Hirakawa H, Goto Y, et al. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, faecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohuku Journal of Experimental Medicine 132: 453–462, 1980CrossRefGoogle Scholar
- McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycaemia using alpha-glucosidase inhibition. Diabetes Care 6: 483–487, 1983PubMedCrossRefGoogle Scholar
- Mies R, Spengler M. Efficacy of the glucosidase inhibitor acarbose compared to the sulphonylurea glisepoxid on metabolic control of type 2 (non — insulin-dependent) diabetes. Diabetologia 30: 557A, 1987Google Scholar
- Moller DE, Hier JS. Insulin resistance — mechanisms, syndromes and implications. New England Journal of Medicine 325: 938–948, 1991PubMedCrossRefGoogle Scholar
- Müller FO, Hillebrand I. Acarbose (BAY g 5421) kinetics in healthy volunteers. Acta Pharmacologica et Toxicologica 59 (Suppl. V): 303, 1986Google Scholar
- Nestel PJ, Bazelmans J, Reardon MF, Boston RC. Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor. Diabete et Metabolisme 11: 316–317, 1985PubMedGoogle Scholar
- O'Dea K, Turton J. Optimum effectiveness of intestinal α-glucosidase inhibitors: importance of uniform distribution through a meal. American Journal of Clinical Nutrition 41: 511–516, 1985PubMedGoogle Scholar
- Petersen K-G. Effects of acarbose in sulphonylurea-treated diabetics in comparison to buformin. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 325–329, Exerpta Medica, Amsterdam, 1982Google Scholar
- Patsch JR, Hopferwieser T, Muhlberger V, Knapp E, Braunsteiner H, et al. Postprandial lipemia in patients with coronary artery disease. Circulation 82 (Suppl. III), abstract no. 1129, 1990Google Scholar
- Pinquier JL, Pello JY, Rey E, de Lauture D, D'Athis P, et al. Effect of acarbose repeated dosing on antipyrine test in healthy volunteers. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 291–294. De Gruyter, Berlin 1992Google Scholar
- Pütter J. Studies on the pharmacokinetics of acarbose in humans. In Brodbeck U (Ed.). Enzyme Inhibitors, pp 139–151, Verlag Chemie, Weinheim, 1980.Google Scholar
- Pütter J, Keup U, Krause HP, Mueller L. Weber H. Pharmacokinetics of acarbose. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp. 38–48, Excerpta Medica, Amsterdam, 1982Google Scholar
- Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13 (Suppl. 3): 32–36, 1990PubMedCrossRefGoogle Scholar
- Raptis S, Dimitriadis G, Etzrodt H, Kraraiskos C, Hadjidakis D, et al. The effects of acarbose treatment on release of pancreatic and gastrointestinal hormones in man. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp. 210-215, Excerpta Medica, Amsterdam, 1982Google Scholar
- Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 329: 304–309, 1993PubMedCrossRefGoogle Scholar
- Richard JL, Rodier M, Monnier L, Orsetti A, Mirouze J. Effect of acarbose on glucose and insulin response to sucrose load in reactive hypoglycaemia. Diabète et Metabolisme 14: 114–118, 1988PubMedGoogle Scholar
- Rodier M, Richard JL, Monnier L, Mirouze J. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent diabetes (type II) mellitus. Diabète et Metabolisme 14: 12–14, 1988PubMedGoogle Scholar
- Ruppin H, Hagel J, Feuerbach W, Schutt H, Pichl J, et al. Fate and effects of the α-glucosidase inhibitor acarbose in humans. An intestinal slow-marker perfusion study. Gastroenterology 95: 93–99, 1988PubMedGoogle Scholar
- Russell JC, Koeslag DG, Dolphin PJ, Amy RM. Beneficial effects of acarbose in the atherosclerosis-prone JCR: LA-corpulent rat. Metabolism 42: 218–223, 1993PubMedCrossRefGoogle Scholar
- Rybka J, Gregorová A, Zmydlena A, Jaron P. Clinical study of acarbose. Drug Investigation 2: 264–267, 1990CrossRefGoogle Scholar
- Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, et al. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 23: 823–828, 1992PubMedCrossRefGoogle Scholar
- Sailer D, Roeder G. Treatment of non-insulin dependent diabetic adults with a new glycoside hydrolase inhibitor (Bay g 5421). Arzneimittel-Forschung 30: 2181–2185, 1980Google Scholar
- Sailer D, Gossner L, Schönfuss I. Einfluss von acarbose auf den Spritz-Ess-Abstand beim typ-1-diabetes. Fortschritte der Medizin 110: 479–480, 1992PubMedGoogle Scholar
- Sakamoto N, Shibata M, Hotta N, Kakuta H, Tomita A, et al. Clinical study on BAY g 5421 (acarbose) for non-insulin-dependent diabetes mellitus (NIDDM). Yakuri to Chiryo 17: 633–649, 1989Google Scholar
- Savage AP, Adrian TE, Carolan G, Chatterjee VK, Polak JM, et al. Effects of peptide YY (PYY) on mouth-caecum intestinal transit and gastric emptying. Gut 28: 166–170, 1987PubMedPubMedCentralCrossRefGoogle Scholar
- Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, Lefèbvre PJ. Reduction of metformin acute bioavailability by the alpha-glucosidase inhibitor acarbose in normal man. Abstract. European Journal of Clinical Investigation 23 (Suppl. 1): A43, 1993Google Scholar
- Scheppach W, Fabian C, Sachs M, Kasper H. The effect of starch malabsorption on fecal short-chain fatty acid excretion in man. Scandinavian Journal of Gastroenterology 26: 755–759, 1988CrossRefGoogle Scholar
- Schöffling K, Petzoldt R, Hillebrand I, Schwedes U. Comparison of metformin and acarbose treatment in non-insulin dependent diabetics (NIDDM): a double-blind cross over study. In Melish J.S., et al. (Eds) Genetic environmental interaction in diabetes mellitus. Proceedings of the Third Symposium on Diabetes Mellitus in Asia and Oceania, Honolulu, February 1981, pp 339-343, Excerpta Medica, Amsterdam, 1982Google Scholar
- Shimoyama T, Hori S, Tamura K, Tanida N, Hosomi M, et al. Effects of acarbose on faecal microflora of hyperlipidaemic patients. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 123-136, Excerpta Medica, Amsterdam, 1982Google Scholar
- Sima AAF, Chakrabarti S. Long-term suppression of postprandial hyperglycaemia with acarbose retards the development of neuropathies in the BBAV-rat. Diabetologia 35: 325–330, 1992PubMedCrossRefGoogle Scholar
- Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 65: 181–189, 1987PubMedCrossRefGoogle Scholar
- Spengler M, Cagatay M. Evaluation of efficacy and tolerability of acarbose by postmarketing surveillance. Diabetes und Stoffwechsel 1: 218–222, 1992aGoogle Scholar
- Spengler M, Cagatay M. Assessment of efficacy and tolerability of acarbose in diabetic patients 5–16 years of age. In Lefebvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 290–294. De Gruyter, Berlin 1992bGoogle Scholar
- Spengler M, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Hormone and Metabolic Research 26 (Suppl.):50–51, 1992aGoogle Scholar
- Spengler M, Hobler H, Cagatay M. Long-term tolerability of acarbose. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 286–288. De Gruyter, Berlin 1992bGoogle Scholar
- Standl E, Janka HU. High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes. Hormone and Metabolic Research 15 (Suppl.): 46–51, 1985Google Scholar
- Stout RW. Insulin and atheroma. 20-year perspective. Diabetes Care 13: 631–654, 1990PubMedCrossRefGoogle Scholar
- Taylor RH, Jenkins DJA, Barker HM, Fielden H, Goff DV, et al. Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption. Diabetes Care 5: 92–96, 1982PubMedCrossRefGoogle Scholar
- Toeller M. Nutritional recommendations for diabetic patients and treatment with α-glucosidase inhibitors. Drugs 44 (Suppl. 3): 13–20, 1992PubMedCrossRefGoogle Scholar
- Tulp OL, Abdollahi A, Stevens C, Schnitzer-Polokoff R. The effects of the intestinal glucosidase inhibitor acarbose on cholesterogenesis in corpulent rats. Biochemical Physiology 100A: 763–768, 1991CrossRefGoogle Scholar
- Tuomilehto J. Acarbose monotherapy in the treatment of non-insulin-dependent diabetes mellitus — a review. In Creutzfeldt W. (Ed.) Proceedings of the Second International Symposium on Acarbose, Berlin, 1987, pp 105-116, Springer-Verlag, 1988Google Scholar
- UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34: 877–890, 1991CrossRefGoogle Scholar
- Uttenthal LO, Ukponmwam OO, Ghiglione M, Bloom SR. Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man. Digestive Diseases and Sciences 32: 139–144, 1987PubMedCrossRefGoogle Scholar
- Van Gaal L, De Leeuw I, Branolte J. Mineral and vitamin absorption during acarbose treatment. In Alberti et al. (Eds) 11th Congress of the International Diabetes Federation, Nairobi, November 1982, p 35, Excerpta Medica, Amsterdam, 1982Google Scholar
- Van Gaal L, Nobels F, De Leeuw I. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Zeitschrift fur Gastroenterologie 29: 642–644, 1991PubMedGoogle Scholar
- Walter-Sack IE, Wolfram G, Zöllner N. Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet. Annals of Nutrition and Metabolism 33: 100–107, 1989PubMedCrossRefGoogle Scholar
- Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341: 1306–1309, 22 May 1993PubMedCrossRefGoogle Scholar
- William-Olsson T. A-glucosidase inhibition in obesity. Acta Medica Scandinavica 706 (Suppl. 1): 1–39, 1985PubMedGoogle Scholar
- William-Olsson T, Krotkiewski M, Sjöström L. Relapse-reducing effects of acarbose after weight reduction in severely obese subjects. Journal of Obesity and Weight Regulation 4: 20–32, 1985Google Scholar
- Willms B. Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 163-176. De Gruyter, Berlin 1992aGoogle Scholar
- Willms B. Therapie des typ-II-diabetes-α-glukosidasehemmer (acarbose). Aktuelle Endokrinologie und Stoffwechsel 13: 51–56, 1992bGoogle Scholar
- Young JC, Kurowski TG, O'Hare T, Vasselli JR, Ruderman NB. Effect of oral α-glucosidase inhibitor BAY g5421 on glucose uptake in skeletal muscle. Abstract. Diabetes 40 (Suppl. 1): 25A, 1991Google Scholar
- Zillikens MC, Swart GR, van den Berg JWO, Wilson JHP. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics. 3: 453–459, 1989PubMedCrossRefGoogle Scholar
- Zimmerman BR. Preventing long term complications. Implications for combination therapy with acarbose. Drugs 44 (Suppl. 3): 54–59, 1992PubMedCrossRefGoogle Scholar


text:
gettex – fast and low cost trading
The gettex trading platform offers reliable prices and immediate execution within the framework of a well-known, reliable exchange marketplace with full transparency, fair pricing and under the supervision of the trading surveillance bodies.
Over 100,000 securities, including over 3,000 stocks and more than 2,500 foreign currency bonds, and that is new - 80.000 certificates can be traded without exchange fees and commission-free on gettex.
All conventional order types as well as "intelligent order types", such as trailing stops, can be entered on gettex. On the website, investors can view real-time prices free of charge and will see the developments on the most important markets and for all traded equities, funds, ETFs, ETCs and bonds at one glance.
New: Certificate Trading
Round about 80.000 certificates issued by "HypoVereinsbank onemarkets" can be traded on gettex starting July 18th. Without exchange fees and commission-free on gettex, that also applies for certificates.
Contact us
Trading Surveillance:
Tel.: +49 89 549045-53
Mail: huest(at)gettex(dot)de


text:
This product is no longer available.
You can try these similar gifts instead.
Am I Cute or What Picture Frame
The mommy-to-be is sure to appreciate such a sweet gift! This colorful blue picture frame features "This is me in my mommy's tummy" on top and "Am I cute, or what?" on the bottom. Cute, indeed!


text:
Free 'terror pack' stunt to promote movie A Belfast Story sparks fury
A man whose father died in an IRA bombing has said he is disgusted by a film director who sent out packs containing a balaclava, nails and duct tape to promote a movie set in Belfast.
Nathan Todd has apologised after the packs were sent to journalists and critics to promote A Belfast Story, which follows a detective investigating the murders of former terrorists.
Mr Todd said the idea was to "interest people" in the film rather than frighten or offend them.
Stephen Gault, whose father Samuel was killed in the 1987 Enniskillen bombing, said the stunt was "highly offensive".
"He is making a mockery of terrorism," Mr Gault told the Belfast Telegraph.
"The balaclava is symbolic of a terrorist but he has used it as a joke – it is completely insensitive.
"It is very hurtful for anyone who has lost a relative at the hands of terrorism."
The film is set in a post-Troubles Belfast still marred by violence and echoes of the past, with Irish actor Colm Meaney starring as a detective investigating the killings of ex-IRA men.
Mr Todd, who studied engineering at Queen's University Belfast, apologised for any offence caused.
"The idea was to interest people in a movie we were making which is essentially the story of the two choices which face Belfast, do we engage retribution or reconciliation," he said. "Obviously, the intention is not to offend anyone. We apologise if we did."
UTV presenter Frank Mitchell, who received one of the packs, said he had been puzzled by its contents.
"My immediate reaction was to question it as strange, not to criticise it," he said.
But movie journalist Chris Hewitt, from Banbridge, branded it "the most distasteful freebie ever".
"Just been sent the most distasteful freebie ever: a box containing a bag of nails (for a nail bomb) and a balaclava, for The Belfast Story," he wrote on Twitter.
"Genuinely stunned by this."
A mechanical engineer by trade, Nathan Todd has become a skilled film-maker. Having been schooled in both Cork and Belfast he has a uniquely Irish perspective on storytelling, with his films often dark, thoughtful and eccentric.
Belfast Telegraph


text:
We may have shut our doors, but as a final farewell we've announced more than £100,000-worth of IdeasTap-funded opportunities on Hiive.
Find out how you can apply...
With the annual London Comic Con opening today, comic writer and artist Emma Vieceli (pictured below) – whose clients include Marvel and Random House – talks to IdeasTap about Shakespeare, Manga and the rise of graphic novels...
How did you become a freelance comic artist and writer?
Being a comic creator was never anything I seriously planned. I don't think I even imagined it could be a real job! I trained as an actress and singer; it was only after I'd been working in theatre and TV for a while that I started making comics as a hobby and joined a group called Sweatdrop. We were just a bunch of friends making comics for fun, the old-fashioned way, and we'd sell them at conventions from a group table.
I was new to the process, so my work wasn't brilliant, but the group was very inspirational (and still is). Eventually, through contacts we had made during conventions and shows, an opportunity arose to pitch to independent publisher SelfMadeHero for a new line of Shakespeare adaptations.
That same year, Tokyopop launched Rising Stars of Manga in the UK, and I was cajoled by my friends into giving that a try too. To my amazement, I got the job to draw an adaptation of Hamlet, and a week later, I learned that I was one of the finalists. I began to receive more contacts and offers for work.
What advice would you give to aspiring comic artists and writers?
Practise as much as you can. Don't set unrealistic goals, start with something achievable: plan a 20-page comic and work on getting that completed and printed. You'll feel amazing when you hold a finished comic in your hands that you can take to an event and sell.
There are so many shows around the UK now. The MCM Expo in London has a large area for comic creators both pro and indie; Bristol, Leeds and Birmingham also run great comic events. Probably one of the most important things in this industry is to socialise and network. It's a scene full of lovely people, so get along to events to meet them and make contact.
Are there many opportunities for comic creators in the UK?
It's a growing scene, though largely in independent press terms. There are more opportunities than ever for creators to print their own work and sell it, and I know people who make a living out of doing this. If you want to work for publishers, you need to be able to think a little broader, but the opportunities are certainly there.
The book industry is really getting excited about comics and so there are more chances to work on adaptations and original titles through amazing publishers like SelfMadeHero and David Fickling books. I feel lucky to be working on the Vampire Academy with Penguin books, and I'm also working on a co-created original series with Oni Press and writers Nunzio DeFilippis and Christina Weir.
How do you think comics and graphic novels fit into the British arts scene?
In the last few years, comics have gone from being seen as something niche to being recognised as a brilliant storytelling medium that can engage young and older readers alike. Comics are getting reviewed and promoted in national newspapers; we've seen Kate Brown receive the first ever Arts Foundation Fellowship for Graphic Novels in 2010; exhibitions of comic art are getting a fantastic response; and films and TV are turning to comics as a source of inspiration.
Have a look at Emma's work on her website.
London MCM Expo: London Comic Con runs from 27 to 29 May 2011, ExCel, Docklands, London.
6881 Page views
The end of an era
Who we support and why
Five common CV mistakes
Five common cover letter mistakes


text:
Select your favourite CD and escape to the Adelaide Hills for an unforgettable driving holiday.
Drive along winding roads, over gentle hills, past neatly planted vineyards, quaint towns and villages.
All are barely 30 minutes drive from Adelaide. Make up your own route or let us do the planning for you. Check out our Adelaide Hills Classic Country Drive suggestions before you hit the road. Then put the top down and enjoy the ride.
Driving from Hahndorf to Birdwood via Woodside and Lobethal is a visual and culinary feast. There's cheese, wine and beer to sample, chocolates to devour and orchards laden with fruit. Linger over a winery lunch or browse for antiques. Set aside enough time to reminisce about your first car at Birdwood's National Motor Museum.
Start with a coffee at Mount Lofty Summit and head to the picturesque Chain of Ponds. The roads on this route are stunning. It's classic Hills' motoring. Before you head off, enjoy panoramic views of Adelaide from the summit. On your driving trip, admire the region's gardens, cuddle animals and take in the views over lunch, before arriving at Chain of Ponds.
The township of Chain of Ponds was demolished in the 1970s to protect water quality in the nearby reservoir. The five-star rated winery and its elegant world class wines were mercifully preserved.
Wetlands, trails and Hills' history dominate the Mount Barker to Jupiter Creek drive. Teeming with wildlife, Mount Barker's Laratinga Wetlands is one of Australia's most successful artificial wetlands.
Take your bike and stop off for a ride through Kuitpo Forest before refuelling at a bakery. In Echunga, revisit Adelaide Hills' gold rush days, with a walk along the Heritage Trail to Jupiter Creek Goldmine.
Enjoy the winding roads from the garden village of Stirling, to historic Hahndorf before indulging in lunch on the deck at the stunning Bridgewater Mill.
The Adelaide Hills is also featured in two self drive itineraries - Best of Adelaide and surrounds and the Great South Australia Wine and Food drive. Why not try them both?
There are plenty of events on in South Australia. Here are some ideas to get you started.
Here are some great ideas for you to try while you're in the area.


text:
Solar Companies Reviews in West Hills, CA
Top rated solar companies in West Hills, California
Search by city
Semper Solaris
Services: Commercial Solar Electric, Residential Solar Electric
Office location: El Cajon, CA 92020
this was a great experience, the system was up and going with in 30days. GREAT JOB.
Services: Solar Hot Water (Thermal), Commercial Solar Electric, Energy Monitoring, Residential Solar Electric, Storage, Energy Audits
Office location: Canoga Park, CA 91303
I looked into a few solar companies and NRG was able to give me the best financing. I was able to pay a quarter of my financing a month compared to my electricity bills so our decision to get solar was very easy. The process was lengthy but Sherry made sure too keep me updated which was very refreshing.... read more
Services: Energy Monitoring, Storage, Commercial Solar Electric, Residential Solar Electric
Sunlux did an excellent job from their sales rep denica who was very thorough to Nick and his crew who installed the system to Justin who did the follow up with final inspection great job guys a friend of mine in the industry referred me to sunlux because the owner is a good straight up guy
The solar installation Imperial Solar has done for us is really a work of art. We never though our solar system would look so good. The designed a system that was both nice and performs well. We were very worried about the solar panels begin an eye sore on the roof. Not so! Quality work done by quality contractor. Great job... read more
Calculate your savings and ROI from
"buying solar panels for your home"
Services: Energy Audits, Commercial Solar Electric, Residential Solar Electric, Energy Monitoring, Storage
A customized 3.6kwp PV Solar System was professionally installed for my 2-story single residence within a day, despite a 55 mile/hr wind gust throughout the day. The courteous staff at the company took care all of the city permit/license paper-works from A-Z. The customized PV Solar system designed by Green Conception and estimated price were thoroughly explained in details with absolute no sale pressure or commitment. If it was not LADWP in the middle, making a serious mistake and delaying the delivery of a new digital NET meter for the project, the entire PV Solar System could have been professionally completed and up running in energy production within a 3-week span. The magnificent installation crew meticulously walked around the site to ensure that no flying debris is left behind after the installation. All conduits joining the system components together were snugly fitted and color painted to match the residence exterior, giving an overall elegance appearance. Highly recommended company for anyone looking forward to make a move to PV Solar Energy.A 360 view of the system at 100 ft:https://youtu.be/CFWpHaSdv68Exterior looks:https://drive.google.com/open?id=1uc0v_CQILQjBChKsuvF4xc2t8FFWhBxNwAhttps://drive.google.com/open?id=1MRO4HUsd6_bHf1Uq3Wvx5tAv0PjbGaHQDAhttps://drive.google.com/open?id=1rhtqWq3JjwI31YLBuJWBIrN_o7MIVKWT8A... read more
Services: Commercial Solar Electric, Residential Solar Electric, Storage, Solar Hot Water (Thermal)
We had a very easy installation experience with the team at Blue Sky Energy. They went above and beyond in explaining and coordinating everything. We are left with a system that is beautifully installed and is overperforming the original estimates, and are extremely happy with their follow up and communication.... read more
Services: Commercial Solar Electric, Residential Solar Electric, Energy Monitoring
Office location: Los Angeles, CA 91406
I shopped solar pretty rigorously and LA Solar was able to deliver on pricing and they offer the best warranties. Joe Hawley, the salesman, has been in the industry for over a decade and was able to educate me and answer all of the questions that I had. I ended up going with the Panasonic 330 panels, they cost more, but you don''t need as many and they are a much better product. As far as installation, the roofing foreman was James, the solar electrician was Vahag and the main panel upgrade electrician was Joseph. They all did a great job leaving my house clean and in good shape when they left. The whole process was quick and easy.I''m very happy with my decision to work with LA Solar. They''re a big company, but not big enough to treat you like the big corporate solar companies treat you.... read more
The people are great, the company is great! Couldn't be more pleased!
How much do solar panels cost in your area
Services: Energy Monitoring, Storage, Energy Audits, Residential Solar Electric
Eric was an excellent salesman and promised everything on the contract. Installation was quick and they were very friendly and neat and answered my questions thru out the installs. Customer service was awesome, always calling me and making sure I was up to date with the project. After support with Robert was very good, he was very knowledgeable and made it easy to learn for my wife and I. If anyone wants to come and look at the work, feel free to check it out on my house by making an appointment with Eric.... read more
Services: Storage, Energy Audits, Commercial Solar Electric, Residential Solar Electric, Energy Monitoring
We had a very good experience overall, the installation experience was the best part of the process. Our installer was so helpful and professional.
Search by city
Average rating for solar companies in West Hills, CA
Best solar companies in West Hills, CA offering quotes online
Highest rated solar companies in West Hills, CA
West Hills covers the following zip codes:
Back to list of Cities in Los Angeles, California
Back to list of Counties in California


text:
Williams Communications Solutions' Upgrade for Dialect Media Queue (DMQ)
Post a comment
Dialect Media Queue (DMQ) from Williams Communications Solutions (Houston, TX) routes customers' e-mail messages, faxes and Web callback requests to agents' PCs. DMQ also works with phone switches from Lucent Technologies, Nortel Networks and Rockwell Electronic Commerce to direct customers' phone calls to agents.
Agents view information about current calls or on-line messages from a queue, as pictured here. The software presents agents with an accompanying screen pop when a new item appears in queue. You can look up an archive of calls and messages your center receives. Administrators create rules to prioritize calls or messages by type of media, which, for example, can ensure that agents respond more quickly to urgent e-mail messages than to calls. Administrators also determine which groups of agents should receive calls, Web callback requests, e-mail or faxes based on the numbers customers dial, the Web pages from where they complete on-line forms or the generic e-mail addresses, such as firstname.lastname@example.com, to which they send messages.
You install DMQ on a dedicated Windows NT server, which you connect to your e-mail, Web and/or fax servers and to a Lucent Definity G3, Lucent ECS, Nortel Meridian 1 or Rockwell Transcend phone switch. DMQ receives messages from each server and can work with your existing ACD to route calls, faxes and on-line messages to agents. Agents, supervisors and administrators run DMQ on PCs that run all current Windows operating systems.
Pricing for DMQ begins at $500 per seat for ten seats. With volume discounts, the per-seat cost can be as low as $150 for 200 seats. You also pay a flat fee of $5,500 that corresponds to each type of server you use with DMQ. For example, if you have two e-mail servers, three fax servers and one Web server, your flat fee, not including per-seat costs, is $16,500 ($5,500 for each type of server). 800-WILLIAMS, www.wilcomsol.com.


text:
Oct 26, 2010 | 352 Pages
"Peter Mansbridge reminds readers why he's one of the most respected interviewers in Canada."
— Ottawa Citizen
"One on One is a wonderful journey involving key events and key players of the past 10 years. Mansbridge writes with self-deprecating, wry humour."
— The Record
"Captures Mansbridge's knack for informing or enlightening, even as he jousts, or empathizes, with his subjects. On television, he makes it look effortless. The book proves it's anything but."
— Winnipeg Free Press
"His solemn, thoughtful presence has been the unofficial brand of CBC News: The National for 21 years. He's pinned down world leaders on his Newsworld show for a decade…. Mansbridge's offerings are some of the best reading in the book."
— Toronto Star
From the Hardcover edition.
Conrad Black
Diana Krall
Karlheinz Schreiber
The Aga Khan
Randy Bachman
Sir Martin Gilbert
Marc Garneau
Devra Davis
Perdita Felicien
The Golfers
Colm Feore
Brian Clark
Hamid Karzai
Roya Rahmani
Tariq Aziz
Brian Wilson
Bill Clinton
Paul Watson
Ellen Johnson-Sirleaf
Duleep de Chickera
Bill Gates
South Africa
The Dalai Lama
First Nations
Israeli PMs
Diana Buttu
Rex Murphy
The Hockey Players
The Prime Ministers
Ted Sorensen
Barack Obama
Final Thoughts
From the Hardcover edition.


text:
Spotlight on Del Mar Week 6
Highlights: Owners Bud and Judy Johnston and family, including their daughter, Mary, and her husband, Pete Hilvers, along with trainer Don Warren won their first ever Pacific Classic with Acclamation, the first horse to win three Grade Is in the country this year and the first ever at Del Mar to win the Eddie Read Stakes and Classic, the latter in Polytrack-record time of 2:00.61 for 1¼ miles . . . jockey Patrick Valenzuela went 20 years between his first Pacific Classic, with John and Betty Mabee's Best Pal, and his second, aboard Johnston-Hilvers' Acclamation, but the 48-year-old warrior can still get a speed horse out of the gate and across the wire as well as anyone in silks . . . The Factor won impressively in the Pat O'Brien Stakes for trainer Bob Baffert and owners George Bolton and Fog City Stable . . . Michael Jawl's Celtic New Year, trained by John Sadler and ridden by Victor Espinoza, upset Bourbon Bay in the Del Mar Handicap . . . Espinoza had two other wins on Classic Day and six for the week to tie Joel Rosario for most wins for the week . . . Caracortado, owned by Don Blahut, trained by Michael Machowsky and ridden by Joe Talamo, won the Del Mar Handicap . . . Private Affair was the big upset winner of the CTT and TOC Handicap for Green Grass Stable and trainer Ruben Cardenas, with newcomer jockey Hector Berrios of Chile . . . John Johny Jak won the Harry F. Brubaker Stakes for Kretz Racing, trainer Kristin Mulhall and Rosario . . . with a Pick Six carryover of $341,252 going into Wednesday, Del Mar likely will get its fifth Pick Six pool to top $1 million this season.
Lowlights: Tyler Baze is 0-for-24 since coming back from his three days off for being over-limit on a Breathalyzer test on Aug. 19. His last win was Aug. 6 aboard owner Nels Erickson's Ultra Blend in the eighth race, the Grade I, Clement L. Hirsch Stakes. He's gone 0-for-55 since . . . Loss of two horses, Sherman's filly, Pedaltothemedal, who broke down on the Polytrack after working Thursday morning, and Our Lady Gaga, who was hurt July 24 trying to avoid a fallen horse, Be Driven, on a race on the Polytrack. Raises the total of deceased horses to eight for the meeting, two from racing on Polytrack, four from morning works on Polytrack and two from turf races . . . attendance is down 0.6 percent (just 114 fans per day off the 18,606 average per day last year) . . . handle is down 4.7 percent, with $16,532,893 less bet this year through Week 6 or 30 days.
Look ahead: The $100,000 Generous Portion Stakes for 2-year-old fillies Wednesday . . . $100,000 El Cajon Stakes for 3-year-olds Friday . . . Grade I, $250,000 Del Mar Debutante for 2-year-old fillies Saturday . . . $100,000 Torrey Pines Stakes for 3-year-old fillies Sunday . . . Grade II, $250,000 Del Mar Derby Sunday . . . $100,000 I'm Smokin Stakes for 2-year-old Cal-Breds Monday . . . Grade II, $150,000 Palomar Handicap Monday . . . Grade I, $250,000 Del Mar Futurity for 2-year-olds is closing day, Wednesday.


text: Over a hundred fashion models literally steps out onto Orchard Road last Saturday night. The stretch of Orchard Road from Ion Orchard to Paragon Mall were turned into a fashion runway as models strut down the road. Seeing these models walk on the road instead of the usual catwalk is refreshing and I believe is the first time that a busy road has been closed and used as a fashion runway.


text:
I originally bought this to do the HTR550 on, but didn't as the fork was away being serviced.
I really like this bike, I did the Lakeland 200 on it, but I need to make some space for a Longitude. I'm the second owner, but like the first, have not used it much.
Cannondale F600 frame and Fatty suspension fork with lockout. (A couple of months back I had this serviced, which cost me £140)
Size is a L, though it is more of a medium. Seatpost 18" C-T. Virtual Top Tube 22.5" C-C I'm 5'10'' 32 inseam.
The frame is currently running XTR V-brakes, but has mounts for discs F+R
The rest of the drivetrain is a mix of XT LX and Deore. All works fine. 3 x 9 gears. ~200 mile old cassette.
The front wheel was built by 18 bikes onto a SP hub. It's done ~200 miles
Hope skewers.
£300 seems a fair price for the lot. £250 if you want the Deore wheel that it originally came with and not the dynamo hub.
No pedals
Collection from the Peak or delivery will be an extra £15, and it may take a couple of days to source a box.


text: The Reader in Gender Archaeology presents nineteen current, controversial and highly influential articles which confront and illuminate issues of gender in prehistory. The articles here, which draw on evidence from a wide range of geographic areas, explore the subject of gender difference and its construction as a natural or cultural one. The contributors demonstrate how archaeological investigation can benefit from an awareness of issues of gender and show how the long-term nature of archaeological research can also inform the gender debate across the disciplines.